|
SLS009 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: GFH009
Birmingham, Alabama1 trial
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
O'Neal Comprehensive Cancer Center, University of Alabama
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.